Aug 9 |
Avidity Biosciences Reports Second Quarter 2024 Financial Results and Recent Highlights
|
Aug 9 |
Avidity Biosciences Announces Positive AOC 1044 Data Demonstrated Significant Increase of 25% in Dystrophin Production and Reduction of Creatine Kinase Levels to Near Normal in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping...
|
Aug 5 |
Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer
|
Jul 24 |
3 Stocks Doing Even Better Than Superstar Super Micro (SMCI)
|
Jul 23 |
3 Russell 2000 Growth Stocks That Could Be Worth the Risk
|
Jul 22 |
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Jul 3 |
Avidity’s FSHD drug del-brax shows promise in Phase I/II trial
|
Jun 20 |
(RNA) - Analyzing Avidity Biosciences's Short Interest
|
Jun 20 |
Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day
|
Jun 19 |
Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)
|